Credit Suisse Downgrades Pharmacyclics To Neutral

Analysts at Credit Suisse downgraded

from Outperform to Neutral. The price target for Pharmacyclics has been raised from $163.00 to $233.00. Pharmacyclics shares have gained 57.09% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period. Pharmacyclics' shares declined 1.75% to $214.00 in pre-market trading.